Key statistics
On Friday, Ovid Therapeutics Inc (1OT:FRA) closed at 1.19, -23.23% below its 52-week high of 1.55, set on Jan 08, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.19 |
|---|---|
| High | 1.19 |
| Low | 1.19 |
| Bid | 1.32 |
| Offer | 1.37 |
| Previous close | 1.21 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 130.18m |
| Free float | 117.40m |
| P/E (TTM) | -- |
| Market cap | 188.77m USD |
| EPS (TTM) | -0.5112 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Announcements
- Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
- Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
- Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
- Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
- Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
- Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
- Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
- Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
- Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
- Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
More ▼
